Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

Rare, deadly, and often missed, some skin cancers develop in areas that rarely see the sun. Scientists are still learning about them, but here's what we know.